CD22 and neoplasm: B-ALL is a neoplasm of precursor lymphoid cells committed to the B-cell lineage, characterized by the expression of CD19, CD22, cytoplasmic CD79a, and/or PAX5, as determined by flow cytometry or immunohistochemistry [5].